The amended product information will provide more specific detail on encephalitis as a known adverse reaction to ...

New Drug Submission meeting scheduled with Health Canada for the third quarter of 2025Initial briefing book submitted for review to the European Medicines Agency WARREN, N.J., July 15, 2025 (GLOBE ...

Hundreds of children and adults with rare forms of cystic fibrosis in England will be able to access “life-changing” new ‘triple-combination’ therapy for the very first time, the NHS has announced.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

The treatment, licensed to Klotho Neurosciences, is based on a technology developed at the Universitat Autònoma de Barcelona (UAB).

On July 10, 2025, the Food and Drug Administration (FDA) announced that it had published more than 200 complete response letters (CRLs), in ...

A new class of South Korean immunotherapy drugs is raising hopes for a breakthrough in the treatment of a rare blood cancer ...

Most European travellers heading to sub-tropical regions know to make sure they're up to date on their vaccinations. While ...

Hundreds of children and adults in England with rare forms of cystic fibrosis will now be able to access a new triple-combinatio ...

The firm also said it would evaluate strategic alternatives for its animal health business and close a prostate cancer vaccine trial.

Britain said it would strike an agreement with Vietnam to make it easier for pharmaceutical firms to sell UK-made medicines in the South-East Asian nation under a new trade strategy that emphasi­ses ...

EU novel food authorizations typically take 2.5 years, and sometimes up to six. For many startups, that’s a death sentence.